Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference
January 03, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL, a Phase 3 Drug candidate, recently granted Breakthrough Therapy designation by the FDA Pivotal study in military-related PTSD to begin this quarter NEW YORK, Jan. 03, 2017 ...
Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA
December 19, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Responding to AtEase study results in military-related PTSD population, FDA agrees to work closely with Tonix to develop and review TNX-102 SL for PTSD as efficiently as possible NEW YORK, Dec. 19,...
Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)
December 08, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Sub-Group Analysis of the Phase 2 AtEase Clinical Study Confirms TNX-102 SL’s Potential Efficacy in Combat-Related PTSD Patients Who are the Most Difficult to Treat New Results Presented in Poster...
Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
December 02, 2016 07:21 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals to Present at 9th Annual LD Micro Main Event Investor Conference
November 30, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results
November 10, 2016 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced financial results for the...
Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD
November 10, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting
November 07, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe® International Partnering Conference
November 02, 2016 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...
Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress
November 01, 2016 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD),...